Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer

• Published in: Journal of clinical medicine Vol. 10; no. 6; p. 1272
• Main Authors: Sabatier, Renaud, Martin, Johan, Vicier, Cécile, Guérin, Mathilde, Monneur, Audrey, Provansal, Magali, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Goncalves, Anthony
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 18.03.2021; MDPI
• Subjects: Blood-brain barrier; Brain cancer; Breast cancer; Cancer; Cancer therapies; Clinical medicine; Data collection; Life Sciences; Medical prognosis; Metastasis; Neurosurgery; Patients; Tumors; brain metastasis; eribulin; metastatic breast cancer
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10061272

The onset of brain metastases (BM) is a major turning point during advanced breast cancer (ABC) evolution, with only few treatment options when local therapies have failed. The therapeutic effect of eribulin, a wildly used drug in the treatment of ABC, remains unclear in this setting. We performed a retrospective observational study to assess eribulin efficacy in patients with ABC who displayed BM at time of eribulin initiation. We collected data from the medical files of all ABC patients who received eribulin at our institution from 2012 until 2020. Our main endpoint was the central nervous system (CNS) progression-free survival. (CNS-PFS). Other evaluation criteria were extra-cranial progression free survival (PFS) and overall survival (OS). Twenty patients with BM monitoring data available were selected out of the 549 who received eribulin during the inclusion period. Fifteen patients (75%) had BM progressive as the best response, three patients (15%) had disease stabilization for more than 6 months and only one patient had a partial response according to RECIST 1.1 criteria. Median CNS-PFS was 3.39 months (95CI (3.02-3.76)). Cox univariate analysis identified molecular subtype as the only prognostic parameter in our cohort, with patients with hormone-receptor positive tumors less likely to experience CNS progression than those with triple-negative MBC (HR = 0.23 (95CI = 0.07-0.80), = 0.021). Median extra-cranial PFS was 2.67 months (95CI (2.33-3.01)). Median OS was 7.68 months (95CI (0-17.41)). Eribulin seems to have only a limited impact on BM evolution. Hormone receptors expression may identify a subset of patients with better BM control.